Dark
Streaming/Mobile
Old Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:09:36 EDT Thu 02 May 2024
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
News for U:CLDX from 2023-05-03 to 2024-05-02 - 27 items
News Releases
In The News
Other
CA
US
Date
Sym
Price
Type
Headline
2024-04-17 08:01
U
U:CLDX
News Release
200
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
2024-03-08 07:00
U
U:CLDX
News Release
200
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
2024-03-05 10:30
U
U:CLDX
News Release
200
Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference
2024-03-05 10:11
U
U:CLDX
News Release
200
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
2024-02-29 21:15
U
U:CLDX
News Release
200
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
2024-02-28 16:01
U
U:CLDX
News Release
200
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
2024-02-26 07:01
U
U:CLDX
News Release
200
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
2024-02-24 14:05
U
U:CLDX
News Release
200
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
2024-02-06 16:01
U
U:CLDX
News Release
200
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
2024-02-05 08:01
U
U:CLDX
News Release
200
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
2023-11-27 16:15
U
U:CLDX
News Release
200
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
2023-11-07 23:15
U
U:CLDX
News Release
200
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
2023-11-07 16:01
U
U:CLDX
News Release
200
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
2023-11-06 06:30
U
U:CLDX
News Release
200
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
2023-11-05 15:00
U
U:CLDX
News Release
200
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
2023-11-02 16:01
U
U:CLDX
News Release
200
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-09-26 07:01
U
U:CLDX
News Release
200
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
2023-09-25 08:31
U
U:CLDX
News Release
200
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
2023-08-08 16:01
U
U:CLDX
News Release
200
Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
2023-07-11 08:01
U
U:CLDX
News Release
200
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
2023-07-06 08:01
U
U:CLDX
News Release
200
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
2023-06-10 10:45
U
U:CLDX
News Release
200
Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
2023-06-08 16:01
U
U:CLDX
News Release
200
Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023
2023-06-02 08:01
U
U:CLDX
News Release
200
Celldex Therapeutics to Present at Jefferies Healthcare Conference
2023-05-31 08:01
U
U:CLDX
News Release
200
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies
2023-05-15 08:01
U
U:CLDX
News Release
200
Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023 ¢ „ ¢
2023-05-04 16:01
U
U:CLDX
News Release
200
Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update